M
Martine Delchambre
Researcher at GlaxoSmithKline
Publications - 11
Citations - 1507
Martine Delchambre is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: RTS,S & Malaria vaccine. The author has an hindex of 9, co-authored 11 publications receiving 1449 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
Kalifa Bojang,Paul Milligan,Margaret Pinder,Laurence Vigneron,Ali Alloueche,Kent E. Kester,W. Ripley Ballou,David J. Conway,William H. H. Reece,Philip Gothard,Lawrence Yamuah,Martine Delchambre,Gerald Voss,Brian Greenwood,Adrian V. S. Hill,Keith P. W. J. McAdam,Nadia Tornieporth,Joe Cohen,Tom Doherty +18 more
TL;DR: RTS,S/AS02 is safe, immunogenic, and is the first pre-erythrocytic vaccine to show significant protection against natural P. falciparum infection in semi-immune adult men in The Gambia.
Journal ArticleDOI
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria
Kent E. Kester,Denise McKinney,Nadia Tornieporth,Christian F. Ockenhouse,D. Gray Heppner,Ted Hall,Urszula Krzych,Martine Delchambre,Gerald Voss,Megan Dowler,Jolie Palensky,Janet Wittes,Joe Cohen,W. Ripley Ballou +13 more
TL;DR: Overall protective efficacy of RTS,S/SBAS2 was 41% (95% confidence interval, 22%-56%; P=.0006).
Journal ArticleDOI
Potent Induction of Focused Th1-Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a Recombinant Plasmodium falciparum Malaria Vaccine
Ajit Lalvani,Philippe Moris,Gerald Voss,Ansar A. Pathan,Kent E. Kester,Roger H. Brookes,Edwin A. M. Lee,M. Koutsoukos,Magdalena Plebanski,Martine Delchambre,Katie L. Flanagan,C. Carton,Moncef M. GlaxoSmithKline Slaoui,C. Van Hoecke,William Ripley Ballou,A. V. S. Hill,Joe Cohen +16 more
TL;DR: RTS, S/SBAS2 is a potent inducer of Th1-type cellular and humoral immunity and its results highlight possible immune mechanisms of protection and have important implications for vaccine design in general.
Journal ArticleDOI
Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
Kent E. Kester,James F. Cummings,Christian F. Ockenhouse,Robin Nielsen,B. Ted Hall,Daniel M. Gordon,Robert Schwenk,Urszula Krzych,Carolyn A. Holland,Gregory Richmond,Megan Dowler,Jackie Williams,Robert A. Wirtz,Nadia Tornieporth,Laurence Vigneron,Martine Delchambre,Marie-Ange Demoitié,W. Ripley Ballou,Joe Cohen,D. Gray Heppner +19 more
TL;DR: In malaria-naïve adults, the efficacy of three-dose RTS,S/AS02 regimens on either a 0, 1, and 3 month schedule or an abbreviated 0, 7, and 28 day schedule was not discernibly different from two previously reported trials of two-dose regimens given at 0,1 month that conferred protection.
Journal ArticleDOI
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults
Kent E. Kester,Denise McKinney,Nadia Tornieporth,Christian F. Ockenhouse,D. Gray Heppner,Ted Hall,Bruce T. Wellde,Katherine White,Peifang Sun,Robert Schwenk,Urszula Krzych,Martine Delchambre,Gerald Voss,Marie-Claude Dubois,Robert A. Gasser,Megan Dowler,Megan A. O’Brien,Janet Wittes,Robert A. Wirtz,Joe Cohen,W. Ripley Ballou +20 more
TL;DR: The two formulations of RTS,S were equally safe and immunogenic, and the lyophilized formulation showed similar levels of efficacy against sporozoite challenge to that conferred by the liquid formulation in previous studies.